This article is more than 5 years old. Information may no longer be current.

Pegaptanib may resolve neovascularization secondary to diabetic retinopathy more completely than laser

Br J Ophthalmol. 2009;93:1474-1478.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal pegaptanib produced complete resolution of retinal neovascularization in active proliferative diabetic retinopathy with improvement in best corrected visual acuity in an open-label, exploratory study.

In the study, 10 patients were randomized to receive a 0.3 mg dose of intravitreal pegaptanib sodium every 6 weeks for 30 weeks and 10 patients received panretinal laser photocoagulation.

In the pegaptanib group, all patients had complete resolution of retinal neovascularization at week 36 compared with two in the laser group. In addition, two patients in the laser group had partial resolution, while four showed persistent active proliferative diabetic retinopathy; two patients from each arm of the study were discontinued from the study because of noncompliance with treatment protocols.

At the end of the study, best corrected visual acuity had changed +5.8 letters in the pegaptanib group compared with –6.0 letters in the panretinal laser photocoagulation group.